International Journal of Infectious Diseases最新文献

{"title":"Overlooked risk factors for European autochthonous strongyloidiasis, Paris, France.","authors":"Benoît Heid-Picard, Marion Parisey, Jade Ghosn, Samia Hamane, Stéphane Bretagne, Geoffroy Liegeon, Nathalie De Castro, Yazdan Yazdanpanah, Nathan Peiffer-Smadja, Sandrine Houzé, Nicolas Argy","doi":"10.1016/j.ijid.2026.108948","DOIUrl":"10.1016/j.ijid.2026.108948","url":null,"abstract":"<p><strong>Objectives: </strong>In non-endemic settings, Strongyloides stercoralis infection is primarily suspected in individuals with a history of travel to tropical regions. However, autochthonous transmission in Europe remains underrecognized. We aimed to identify epidemiological and clinical risk factors for strongyloidiasis in a temperate setting.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter study in six Parisian university hospitals including patients diagnosed with confirmed strongyloidiasis between 2014 and 2019. Epidemiological, clinical, and biological characteristics were analyzed to identify populations at risk.</p><p><strong>Results: </strong>Among 74 patients included, 65 (87.8%) had infections associated with travel to highly endemic tropical regions, whereas 9 (12.2%) were classified as European cases, including five men who have sex with men (MSM) living in Mainland France and four individuals originating from South-Eastern Europe. While infections among travelers returning from highly endemic regions were predominantly asymptomatic, European cases were more frequently symptomatic and included two cases of hyperinfection syndrome, one of which was fatal.</p><p><strong>Conclusion: </strong>Although imported infections remain predominant presentation of strongyloidiasis in Mainland France, MSM and individuals originating from South-Eastern Europe appear to represent overlooked populations at risk. Screening strategies should therefore be extended to these groups, particularly before immunosuppressive therapy or in the presence of eosinophilia or compatible clinical manifestations.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108948"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148381982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent onchocerciasis after 24 years of ivermectin mass treatment in the Democratic Republic of the Congo: a cross-sectional analytical study.","authors":"J C Makenga Bof, Rosette Tshilanda Disulayi, Grace Musungu Ngongo, Jonathan Kamba Mbuyi, Alphonsine Ntumba Bakualufu, Kipika Ngongo Ebondo, Sylvain Kabasele Badibanga","doi":"10.1016/j.ijid.2026.108943","DOIUrl":"10.1016/j.ijid.2026.108943","url":null,"abstract":"<p><strong>Objectives: </strong>Despite more than two decades of community-directed treatment with ivermectin (CDTI), onchocerciasis remains endemic in several parts of sub-Saharan Africa, including the Democratic Republic of the Congo (DRC). Suboptimal therapeutic coverage and environmental factors may hinder progress toward elimination.</p><p><strong>Methods: </strong>We conducted a cross-sectional analytical study between June and December 2025 in five health zones of Kasai Central, DRC. Individuals aged ≥5 years and residing in the area for at least five years were selected using multistage stratified sampling. Onchocerciasis infection was assessed using OV16 serology, clinical examination, and targeted skin snip microscopy. Associations between cumulative ivermectin exposure, environmental factors, and prevalence were assessed using regression analyses.</p><p><strong>Results: </strong>A total of 1087 participants were included (median age 29 years; 51.2% female). Overall onchocerciasis prevalence was 19.1% (208/1087; 95% CI: 16.8-21.5), with significant heterogeneity across health zones (14.2-24.9%, P < 0.001). Individuals with fewer than ten ivermectin treatments had higher prevalence than those with ≥10 treatments (25.5% vs 11.3%, P < 0.001). In multivariable analysis, fewer than ten ivermectin treatments (aOR = 2.45; 95% CI: 1.78-3.36; P < 0.001) and residence within 5 km of a river (aOR = 1.96; 95% CI: 1.42-2.70; P < 0.001) were independently associated with infection. At the area level, higher cumulative therapeutic coverage was inversely associated with prevalence (β = -0.39 per 10% increase; 95% CI: -0.52 to -0.26; P < 0.001), while proximity to rivers was positively associated with infection. However, these area-level findings should be interpreted with caution due to the limited number of health zones included in the analysis.</p><p><strong>Conclusion: </strong>After more than 20 years of CDTI, onchocerciasis transmission persists in Kasai Central, with marked spatial heterogeneity. Strengthening treatment coverage and targeting high-risk riverine areas are critical to accelerate elimination efforts in the DRC.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108943"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148368359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salmonella bacteremia: Serotypes, resistance, and outcomes in a tertiary care setting.","authors":"Aghareed Aljohani, Maha Alfarhan, Nouf Alqahtani, Abdulrahman Alsaedy, Bassam Alalwan, Sameera Aljohani, Abdulellah Almohaya, Mohammad Bosaeed","doi":"10.1016/j.ijid.2026.108884","DOIUrl":"10.1016/j.ijid.2026.108884","url":null,"abstract":"<p><strong>Objectives: </strong>Salmonella bloodstream infection (BSI) remains a major cause of morbidity and mortality worldwide, particularly with increasing antimicrobial resistance. We evaluated the clinical characteristics, serogroups, resistance patterns, and outcomes of Salmonella BSI in a tertiary hospital in Saudi Arabia.</p><p><strong>Methods: </strong>A retrospective study at King Abdulaziz Medical City-Riyadh including all patients with Salmonella BSI from January 2016 to July 2024. Demographic, clinical, microbiological, and outcome data were analyzed using descriptive and multivariate methods.</p><p><strong>Results: </strong>A total of 102 patients were included (mean age 57.2 ± 19.9 years; 54.9% male). Group D (46.1%) and Group B (32.4%) were the predominant serogroups. Susceptibility was high to ceftriaxone (98%) and carbapenems (100%), whereas 31.4% of isolates were non-susceptible to ciprofloxacin. Clinical recovery within 14 days occurred in 73.5% of patients. Thirty-day mortality was 14.7%, and recurrence occurred in 4.9%.</p><p><strong>Conclusion: </strong>Salmonella bacteremia remains a significant infection in high-risk populations. Increasing ciprofloxacin resistance highlights the need for optimized empiric therapy and strengthened antimicrobial stewardship. Ongoing local surveillance is essential to guide treatment strategies and improve outcomes.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108884"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148264220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and microbiological features of critical Clade Ib mpox in adults with HIV during a Ugandan outbreak.","authors":"Raymond Ernest Kaweesa, Geoffrey Odoch, Brenda Nairuba, Peter Ejou, Joseph Ssebwana Katende, Syrus Semawule, Annie Daphine Ntabadde, Violet Ankunda, Gathoni Kamuyu, Michael Selorm Avumegah, John Bosco Nsubuga, Edward Kiyonga, Christopher Nsereko, Pontiano Kaleebu, Jennifer Serwanga","doi":"10.1016/j.ijid.2026.108919","DOIUrl":"10.1016/j.ijid.2026.108919","url":null,"abstract":"<p><strong>Objectives: </strong>Severe mpox in people living with HIV remains poorly characterized in African settings experiencing Clade 1b transmission. We characterized the clinical, virological, microbiological, and immunopathological features of critical illness during the 2025 mpox outbreak in Uganda.</p><p><strong>Methods: </strong>We conducted a prospective cohort study of 155 consecutively hospitalized adults with mpox in Uganda between 3 March and 10 April 2025 and performed a nested analysis of critically ill participants. Critically ill participants with sequencing-confirmed Clade Ib infection underwent compartment-specific MPXV PCR testing, lesion bacterial culture and antimicrobial susceptibility testing, HIV viral load assessment, and routine hematological and biochemical investigations.</p><p><strong>Results: </strong>Ten of 155 participants (6.5%) developed critical illness, including four deaths, four severe non-ICU cases, and two ICU admissions. All were people living with HIV. MPXV DNA was consistently detected in skin, genital, and oral/saliva specimens, with substantially lower detection in plasma. Purulent lesion cultures were positive in 9/9 participants and yielded Gram-negative bacilli, Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus species, demonstrating resistance to multiple commonly used antibiotics. Critically ill participants exhibited anemia, neutrophilia, relative lymphopenia, hypoalbuminemia, hyperbilirubinemia, and elevated C-reactive protein. Most survivors cleared MPXV DNA during follow-up, whereas persistent plasma and anal MPXV DNA detection was observed in one participant who subsequently died.</p><p><strong>Conclusion: </strong>Critical Clade 1b mpox in adults with HIV was characterized by high mucocutaneous viral burden, frequent bacterial superinfection with antimicrobial resistance, and marked systemic inflammatory abnormalities. These findings support integrated management strategies incorporating mucocutaneous diagnostics, antimicrobial stewardship, inflammatory monitoring, and optimization of HIV care.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108919"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148317034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When institutional transitions interrupt prevention: 3HP tuberculosis preventive treatment continuity in a Paraguayan prison cohort.","authors":"Gladys Estigarribia, Guillermo Sequera, Diana Medina, Julieta Méndez-Romero, Sarita Aguirre, Angelica Medina, Catalina Segovia, Ana Santacruz, Patricia Rios, Natalia Sosa, Elizabeth Mendieta, Julio Torales","doi":"10.1016/j.ijid.2026.108962","DOIUrl":"10.1016/j.ijid.2026.108962","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate continuity of once-weekly isoniazid plus rifapentine for 12 weeks (3HP) tuberculosis preventive treatment in a Paraguayan prison cohort, focusing on adherence, strict completion, safety and institutional transitions as drivers of non-completion.</p><p><strong>Methods: </strong>We conducted a longitudinal implementation cohort study at Coronel Oviedo Penitentiary Center, Paraguay, during July-October 2025. Persons with QuantiFERON-TB Gold Plus-confirmed tuberculosis infection and active tuberculosis excluded by the program algorithm were offered 3HP under directly observed therapy. Weekly dose administration, missed-dose reasons and self-reported adverse reactions were recorded.</p><p><strong>Results: </strong>Of 1846 people incarcerated in the facility, 240 accessed QuantiFERON testing and 170 tested positive. Among QFT-positive individuals, 50 did not initiate 3HP because of transfer, release or refusal. A total of 120 initiated 3HP; 90 achieved acceptable adherence, defined as receipt of at least 11 of 12 doses (75.0%), and 82 completed all 12 doses (68.3%). Medication was administered in 1195 of 1440 scheduled person-weeks (83.0%). Non-completion occurred in 30 participants; 28 cases (93.3%) were attributable to release or transfer. Fifty-seven participants (47.5%) reported at least one adverse reaction, mostly mild or moderate.</p><p><strong>Conclusion: </strong>High adherence was achieved with 3HP, but institutional transitions interrupted completion, highlighting the need for prison-to-community continuity mechanisms after incarceration.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108962"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of the 4CMenB vaccine against gonorrhea among men who have sex with men in Hong Kong: A double-blind randomized placebo-controlled trial.","authors":"Tsz Ho Kwan, Denise Pui Chung Chan, Christopher Koon Chi Lai, Teddy Tai-Ning Lam, Chi Keung Kwan, Shui Shan Lee","doi":"10.1016/j.ijid.2026.108926","DOIUrl":"10.1016/j.ijid.2026.108926","url":null,"abstract":"<p><strong>Introduction: </strong>The emergence of antimicrobial-resistant gonorrhea among men who have sex with men (MSM) demands new prevention strategies. This study aimed to assess the efficacy of the four-component meningococcal group B (4CMenB) vaccine against gonorrhea among MSM.</p><p><strong>Methods: </strong>A prospective, randomized, double-blind, placebo-controlled trial (NCT05766904) was conducted in Hong Kong in 2023-2024. In total, 152 MSM aged between 18 and 50 years were randomized to either the vaccination or control arm in a 1:1 ratio using permuted blocks of four. Participants received two injections at least 1 month apart and attended three-monthly follow-ups for 2 years. The primary outcome was the incidence of the first gonorrhea episode in the first year.</p><p><strong>Results: </strong>Gonorrhea incidence in the two arms was comparable (control arm 0.78 (95% confidence interval [CI] 0.64-0.95); vaccine arm 0.86 (95% CI 0.77-0.96); hazard ratio 0.76, 95% CI 0.31-1.87). Participants in the vaccine arm were more likely to experience adverse effects, be less worried about acquiring gonorrhea (adjusted odds ratio 2.10, 95% CI 1.22-3.59), and have a lower condom use rate after unblinding.</p><p><strong>Conclusions: </strong>The results did not show efficacy of the 4CMenB vaccine against gonorrhea in MSM. Receipt of the vaccine may impact risk perception and behavioral practices, thus affecting vaccinees' exposure risk to sexually transmitted infections.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108926"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148338531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The single venipuncture, two-set sampling method for blood cultures in Japan.","authors":"Itaru Nakamura, Riho Plubo, Yuri Miura, Ayaka Umeda, Rumiko Imura, Yuki Watanabe, Tomohide Shimodaira, Hidehiro Watanabe","doi":"10.1016/j.ijid.2026.108947","DOIUrl":"10.1016/j.ijid.2026.108947","url":null,"abstract":"<p><strong>Objectives: </strong>Reported advantages of the single-venipuncture, two-set sampling method (single sampling) for blood cultures include improved microbial detection sensitivity and a reduction of contamination rates, and puncture discomfort.</p><p><strong>Methods: </strong>This retrospective longitudinal study investigated the outcome of converting from the multi-sampling to the single-sampling method. The multi-sampling method was employed from January 1, 2023, to June 31, 2024, and the single-sampling method was employed from October 1, 2024, to December 31, 2025. The number of blood cultures submitted, two-set sampling rate, contamination rates, and antimicrobial use density (AUD) and days of therapy (DOT) of vancomycin (VCM) during these two periods were compared.</p><p><strong>Results: </strong>The average number of blood culture bottles per 1000 patient-days and two-set sampling rate (%) per month were significantly higher in the single-sampling method (76.93 and 75.6%) than in the multi-sampling method (70.81 and 72.4%, P < 0.05). The contamination rate decreased significantly from 0.56% in multi-sampling method to 0.38% in the single-sampling method (P < 0.05). The AUD and DOT of VCM decreased from 1.27 to 1.00 and from 1.80 to 1.33, respectively (P < 0.05).</p><p><strong>Conclusion: </strong>Use of the single-sampling method resulted in increased bottles and two-set rates, with decreased contamination rates and VCM administration.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108947"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A protracted course of cutaneous protothecosis: Overcoming recurrence and treatment challenges.","authors":"Suxing Li, Yamei Lu, Dafu Yang, Jiefeng Yang, Rilun Li, Chengfu Li, Shangbao Huang, Lingui Li, Jian Guo","doi":"10.1016/j.ijid.2026.108970","DOIUrl":"10.1016/j.ijid.2026.108970","url":null,"abstract":"<p><p>This report describes a case of chronic, recurrent cutaneous and soft tissue infection caused by Prototheca wickerhamii in a 50-year-old male, presenting with recurrent skin ulcers and abscess formation. The patient had a history of grade 3 hypertension and gout, along with a record of irregular glucocorticoid use. The clinical course was protracted, spanning nearly two years and involving three hospital admissions with a complex treatment trajectory. The isolate was identified as P. wickerhamii through mass spectrometry and CYTB sequencing. In vitro susceptibility testing demonstrated that amphotericin B (AMB) exhibited potent activity against the P. wickerhamii isolate. While the initial treatment phase was complicated by early missed diagnosis and poor patient adherence, leading to recurrent relapses, a significant therapeutic response was ultimately achieved by employing a comprehensive strategy combining intravenous administration with intralesional injection of AMB for refractory lesions. This case highlights the importance of broadening the differential diagnosis for chronic, nonhealing ulcers in immunocompromised hosts to include protothecosis. Furthermore, it underscores that management should be guided by antimicrobial susceptibility testing; for refractory localized lesions, aggressive local injection therapy is a viable option, and strict adherence management is crucial to minimize the risk of recurrence.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108970"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis\" [International Journal of Infectious Diseases, Volume 138 (January 2024), Pages 41-45].","authors":"M Suárez, A Pérez-Landeiro, A Sanjurjo, O Lima, A Sousa, A López, L Martínez-Lamas, X Cabrera, M Rubianes, M T Pérez-Rodríguez","doi":"10.1016/j.ijid.2026.108901","DOIUrl":"10.1016/j.ijid.2026.108901","url":null,"abstract":"","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"170 ","pages":"108901"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of circulating hepatitis C virus genotypes and drug-resistant variants in former Soviet Union countries: A scoping review with genotype meta-analysis.","authors":"Omega Mathew Immanuel, Olaoluwa Tolulope Fabiyi, Zhanar Issabekova, Kuat P Oshakbayev, Gulzhan Abuova, Aliya Konysbekova, Sreenu B Vattipally, Ram Bajpai, Syed Hani Abidi","doi":"10.1016/j.ijid.2026.108871","DOIUrl":"10.1016/j.ijid.2026.108871","url":null,"abstract":"<p><strong>Background: </strong>Despite high hepatitis C virus (HCV) prevalence in the Former Soviet Union (FSU), data on genotype distribution and resistance-associated substitutions (RAS) remain fragmented. This study aims to map the breadth of molecular epidemiological evidence on HCV genotypes and resistance in FSU.</p><p><strong>Method: </strong>We performed a scoping review with a genotype meta-analysis of 24 cross-sectional studies published in PubMed, Web of Science, and Google Scholar from 1990 to 2025. The systematic review was registered with PROSPERO (CRD420251140060).</p><p><strong>Results: </strong>The pooled prevalence of the major HCV genotypes (G1, G2, and G3) was 98.02% (95% CI: 96.71-98.94%), with G1 having the highest prevalence (59%), followed by G3 (27%). G1 was highest in the Mixed Region (73.5%) and lowest in the South Caucasus (30.6%), G2 was highest in the Southern Caucasus (16.8%), and G3 was highest in Eastern Europe (34.5%). Crucially, baseline RAS data were severely limited, with only four small studies (n = 329) from Russia and Georgia reporting clinically significant RAS (NS5A-A30K, Y93H).</p><p><strong>Conclusion: </strong>This study confirms G1 and G3 as the predominant circulating HCV genotypes in the FSU and highlights the near absence of data on RAS. Achieving HCV elimination in this region depends on both strengthening the care cascade and implementing robust virological surveillance systems.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108871"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148217683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}